Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

Similar articles for PubMed (Select 11755456)

1.

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms.

Peet M, Horrobin DF; E-E Multicentre Study Group.

J Psychiatr Res. 2002 Jan-Feb;36(1):7-18.

PMID:
11755456
3.

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

Lewis SW, Davies L, Jones PB, Barnes TR, Murray RM, Kerwin R, Taylor D, Hayhurst KP, Markwick A, Lloyd H, Dunn G.

Health Technol Assess. 2006 May;10(17):iii-iv, ix-xi, 1-165.

4.

Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M.

J Clin Psychiatry. 2004 Apr;65(4):551-6.

PMID:
15119920
6.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
7.

Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison.

Shaw P, Sporn A, Gogtay N, Overman GP, Greenstein D, Gochman P, Tossell JW, Lenane M, Rapoport JL.

Arch Gen Psychiatry. 2006 Jul;63(7):721-30.

PMID:
16818861
8.
9.

Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.

Atmaca M, Kuloglu M, Tezcan E, Ustundag B.

J Clin Psychiatry. 2003 May;64(5):598-604.

PMID:
12755665
10.

Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study.

Lindenmayer JP, Czobor P, Volavka J, Lieberman JA, Citrome L, Sheitman B, Chakos M, McEvoy JP.

J Clin Psychiatry. 2002 Oct;63(10):931-5.

PMID:
12416603
11.

Switching to olanzapine from previous antipsychotics: a regional collaborative multicenter trial assessing 2 switching techniques in Asia Pacific.

Lee CT, Conde BJ, Mazlan M, Visanuyothin T, Wang A, Wong MM, Walker DJ, Roychowdhury SM, Wang H, Tran PV.

J Clin Psychiatry. 2002 Jul;63(7):569-76.

PMID:
12143912
12.

A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.

Anil Yağcioğlu AE, Kivircik Akdede BB, Turgut TI, Tümüklü M, Yazici MK, Alptekin K, Ertuğrul A, Jayathilake K, Göğüş A, Tunca Z, Meltzer HY.

J Clin Psychiatry. 2005 Jan;66(1):63-72.

PMID:
15669890
13.

Effects of clozapine on psychiatric symptoms, cognition, and functional outcome in schizophrenia.

Manschreck TC, Redmond DA, Candela SF, Maher BA.

J Neuropsychiatry Clin Neurosci. 1999 Fall;11(4):481-9.

PMID:
10570762
14.

Efficacy and tolerability of ziprasidone versus risperidone as augmentation in patients partially responsive to clozapine: a randomised controlled clinical trial.

Zink M, Kuwilsky A, Krumm B, Dressing H.

J Psychopharmacol. 2009 May;23(3):305-14. doi: 10.1177/0269881108089593. Epub 2008 Jun 18.

PMID:
18562423
15.

Practical issues with amisulpride in the management of patients with schizophrenia.

Pani L, Villagrán JM, Kontaxakis VP, Alptekin K.

Clin Drug Investig. 2008;28(8):465-77. Review.

PMID:
18598092
16.

Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia.

Bitter I, Dossenbach MR, Brook S, Feldman PD, Metcalfe S, Gagiano CA, Füredi J, Bartko G, Janka Z, Banki CM, Kovacs G, Breier A; Olanzapine HGCK Study Group.

Prog Neuropsychopharmacol Biol Psychiatry. 2004 Jan;28(1):173-80.

PMID:
14687871
17.

Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.

Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy JP, Cooper TB, Chakos M, Lieberman JA.

Am J Psychiatry. 2002 Feb;159(2):255-62. Erratum in: Am J Psychiatry 2002 Dec;159(12):2132.

PMID:
11823268
18.

Clozapine-induced QEEG changes correlate with clinical response in schizophrenic patients: a prospective, longitudinal study.

Gross A, Joutsiniemi SL, Rimon R, Appelberg B.

Pharmacopsychiatry. 2004 May;37(3):119-22.

PMID:
15138895
19.

Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.

Godleski LS, Goldsmith LJ, Vieweg WV, Zettwoch NC, Stikovac DM, Lewis SJ.

J Clin Psychiatry. 2003 Feb;64(2):119-22.

PMID:
12633119
20.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk